Author

D. E. Ferrell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:non-human primate· 4 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. C. Walls· 3 shared K. Rogers· 3 shared M. C. Miranda· 3 shared R. Rappuoli· 3 shared B. Fiala· 2 shared B. Pulendran· 2 shared C. Sydeman· 2 shared C.-L. Hsieh· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. C. Walls

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo

J. Kime, D. Bose, M. Arainga, M. R. Haque, C. M. Fennessey, R. A. Caddell, Y. Thomas, D. E. Ferrell, S. Ali, E. Grody, Y. Goyal, C. Cicala, J. Arthos, B. F. Keele, M. Vaccari, , E. Marinelli

TGF-β blockade with galunisertib reverses SIV latency, reduces viral reservoirs, and enhances immune responses in ART-treated macaques without systemic inflammation.

bioRxiv · Sep 5, 2023Immunology

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology